ACRV (Acrivon Therapeutics) רווח נקי למניה (EPS TTM)

Acrivon Therapeutics (ACRV) dominates targeted oncology through its AP3 AI platform, outpacing industry behemoths. Innovations in precision proteomics and the launch of CHK1/2 inhibitors are transforming diagnostics. Flexibility is ensured by the full outsourcing of production and trials. The 12-month rolling income per unit illustrates financial stability, where -1.91 describes the current status of the metric.

Earnings per share (EPS TTM) measures the portion of profit allocated to each ordinary share over a year. The calculation excludes the impact of equity dilution, demonstrating the actual efficiency of income generation. By analyzing the net income per share over the last 12 months, an investor assesses the pace of business recovery. For Acrivon Therapeutics (ACRV), this metric reflects the financial impact of implementing AI in the search for targeted drugs. Strategic alliances in oncology directly determine future profit capitalization.